image
Healthcare - Drug Manufacturers - Specialty & Generic - NASDAQ - IL
$ 1.17
-6.4 %
$ 53.5 M
Market Cap
-3.08
P/E
1. INTRINSIC VALUE

InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Israel and internationally. It offers dried cannabis inflorescences and cannabis extract mixed with oil. The company also invests in biomed sector. InterCure Ltd. was incorporated in 1994 and is headquartered in Herzliya, Israel.[ Read More ]

The intrinsic value of one INCR stock under the base case scenario is HIDDEN Compared to the current market price of 1.17 USD, InterCure Ltd. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart INCR

image
FINANCIALS
356 M REVENUE
-8.52%
-41.6 M OPERATING INCOME
-78.72%
-63.5 M NET INCOME
-145.22%
-53.6 M OPERATING CASH FLOW
-104.61%
4.77 M INVESTING CASH FLOW
103.35%
-82.9 M FINANCING CASH FLOW
-68.82%
62.9 M REVENUE
0.00%
5.26 M OPERATING INCOME
0.00%
716 K NET INCOME
0.00%
0 OPERATING CASH FLOW
0.00%
0 INVESTING CASH FLOW
0.00%
0 FINANCING CASH FLOW
0.00%
Balance Sheet Decomposition InterCure Ltd.
image
Current Assets 419 M
Cash & Short-Term Investments 101 M
Receivables 61.1 M
Other Current Assets 256 M
Non-Current Assets 368 M
Long-Term Investments 1.92 M
PP&E 97.5 M
Other Non-Current Assets 268 M
Current Liabilities 226 M
Accounts Payable 78.4 M
Short-Term Debt 92.8 M
Other Current Liabilities 54.6 M
Non-Current Liabilities 104 M
Long-Term Debt 103 M
Other Non-Current Liabilities 841 K
EFFICIENCY
Earnings Waterfall InterCure Ltd.
image
Revenue 356 M
Cost Of Revenue 250 M
Gross Profit 105 M
Operating Expenses 150 M
Operating Income -41.6 M
Other Expenses 22 M
Net Income -63.5 M
RATIOS
29.56% GROSS MARGIN
29.56%
-11.69% OPERATING MARGIN
-11.69%
-17.43% NET MARGIN
-17.43%
-13.61% ROE
-13.61%
-7.88% ROA
-7.88%
-6.89% ROIC
-6.89%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis InterCure Ltd.
image
Net Income -63.5 M
Depreciation & Amortization 13.2 M
Capital Expenditures -2.62 M
Stock-Based Compensation 2.59 M
Change in Working Capital -43.5 M
Others 22.8 M
Free Cash Flow -56.2 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets InterCure Ltd.
image
INCR has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership InterCure Ltd.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
7 years ago
Sep 18, 2017
Sell 255 K USD
Gaenzle Christopher L
CAO, GC & Sec
- 4682
54.555 USD
7 years ago
Sep 18, 2017
Sell 529 K USD
Rush Gregory S
Chief Financial Officer
- 9703
54.478 USD
7 years ago
Sep 01, 2017
Sell 1.13 M USD
Rush Gregory S
Chief Financial Officer
- 19300
58.598 USD
7 years ago
Sep 01, 2017
Sell 965 K USD
Rush Gregory S
Chief Financial Officer
- 16202
59.535 USD
7 years ago
Sep 01, 2017
Sell 108 K USD
Rush Gregory S
Chief Financial Officer
- 1834
58.681 USD
7 years ago
Sep 01, 2017
Sell 692 K USD
Rush Gregory S
Chief Financial Officer
- 11834
58.445 USD
7 years ago
Sep 01, 2017
Sell 237 K USD
Rush Gregory S
Chief Financial Officer
- 4066
58.387 USD
7 years ago
Sep 01, 2017
Sell 2.1 M USD
Rush Gregory S
Chief Financial Officer
- 35503
59.21 USD
7 years ago
Aug 30, 2017
Sell 2.07 M USD
Rush Gregory S
Chief Financial Officer
- 35503
58.27 USD
7 years ago
Aug 30, 2017
Sell 344 K USD
Rush Gregory S
Chief Financial Officer
- 5917
58.217 USD
7 years ago
Sep 01, 2017
Sell 603 K USD
Gaenzle Christopher L
CAO, GC & Sec
- 10198
59.099 USD
7 years ago
Sep 01, 2017
Sell 97.5 K USD
Gaenzle Christopher L
CAO, GC & Sec
- 1636
59.602 USD
7 years ago
Sep 01, 2017
Sell 554 K USD
Gaenzle Christopher L
CAO, GC & Sec
- 9467
58.467 USD
7 years ago
Sep 01, 2017
Sell 276 K USD
Gaenzle Christopher L
CAO, GC & Sec
- 4733
58.352 USD
7 years ago
Sep 01, 2017
Sell 278 K USD
Gaenzle Christopher L
CAO, GC & Sec
- 4733
58.674 USD
7 years ago
Sep 01, 2017
Sell 692 K USD
Gaenzle Christopher L
CAO, GC & Sec
- 11834
58.455 USD
7 years ago
Aug 30, 2017
Sell 2.07 M USD
Rush Gregory S
Chief Financial Officer
- 35503
58.27 USD
7 years ago
Aug 30, 2017
Sell 344 K USD
Rush Gregory S
Chief Financial Officer
- 5917
58.217 USD
7 years ago
Jul 03, 2017
Sell 56 K USD
Gaenzle Christopher L
CAO, GC & Sec
- 956
58.55 USD
7 years ago
Jun 30, 2017
Sell 345 K USD
Gaenzle Christopher L
CAO, GC & Sec
- 5917
58.285 USD
7 years ago
Apr 03, 2017
Sell 216 K USD
Gaenzle Christopher L
CAO, GC & Sec
- 4733
45.7 USD
7 years ago
Jan 20, 2017
Sell 59.4 K USD
Gaenzle Christopher L
CAO, GC & Sec
- 1186
50.089 USD
7 years ago
Jan 20, 2017
Sell 79.4 K USD
Rush Gregory S
Executive VP and CFO
- 1573
50.5 USD
7 years ago
Jan 19, 2017
Sell 67.6 K USD
Rush Gregory S
Executive VP and CFO
- 1334
50.65 USD
7 years ago
Jan 03, 2017
Sell 302 K USD
Gaenzle Christopher L
CAO, GC & Sec
- 5817
51.902 USD
7 years ago
Jan 03, 2017
Sell 5.22 K USD
Gaenzle Christopher L
CAO, GC & Sec
- 100
52.25 USD
7 years ago
Jan 03, 2017
Sell 246 K USD
Gaenzle Christopher L
CAO, GC & Sec
- 4733
51.892 USD
7 years ago
Jan 03, 2017
Sell 246 K USD
Gaenzle Christopher L
CAO, GC & Sec
- 4733
51.907 USD
7 years ago
Jan 03, 2017
Sell 1.81 M USD
Rush Gregory S
Executive VP and CFO
- 34903
51.893 USD
7 years ago
Jan 03, 2017
Sell 297 K USD
Rush Gregory S
Executive VP and CFO
- 5717
51.894 USD
7 years ago
Jan 03, 2017
Sell 31.4 K USD
Rush Gregory S
Executive VP and CFO
- 600
52.398 USD
7 years ago
Jan 03, 2017
Sell 10.5 K USD
Rush Gregory S
Executive VP and CFO
- 200
52.4 USD
8 years ago
Sep 30, 2016
Sell 1.59 M USD
Rush Gregory S
Executive VP and CFO
- 35503
44.698 USD
8 years ago
Sep 27, 2016
Sell 620 K USD
Macdonald D. Jamie
Chief Executive Officer
- 13989
44.301 USD
8 years ago
Sep 27, 2016
Sell 787 K USD
Macdonald D. Jamie
Chief Executive Officer
- 17752
44.307 USD
8 years ago
Sep 27, 2016
Sell 146 K USD
Macdonald D. Jamie
Chief Executive Officer
- 3293
44.313 USD
8 years ago
Sep 27, 2016
Sell 839 K USD
Macdonald D. Jamie
Chief Executive Officer
- 18936
44.3005 USD
8 years ago
Sep 26, 2016
Sell 336 K USD
Breckon Robert W
Director
- 7600
44.18 USD
8 years ago
Sep 26, 2016
Sell 1.7 K USD
Breckon Robert W
Director
- 38
44.61 USD
8 years ago
Sep 26, 2016
Sell 201 K USD
Breckon Robert W
Director
- 4559
44.124 USD
8 years ago
Sep 19, 2016
Bought 43.2 K USD
Burgstahler David F
director, 10 percent owner:
+ 1000
43.1868 USD
8 years ago
Sep 14, 2016
Sell 204 K USD
Gaenzle Christopher L
CAO, GC & Sec
- 4734
43.142 USD
8 years ago
Aug 04, 2016
Sell 103 M USD
ONTARIO TEACHERS PENSION PLAN BOARD
director, 10 percent owner:
- 2445591
42.06 USD
8 years ago
Aug 02, 2016
Sell 1.34 M USD
Macdonald D. Jamie
Chief Executive Officer
- 31279
43 USD
8 years ago
Aug 01, 2016
Sell 4.54 K USD
Breckon Robert W
Director
- 108
42 USD
8 years ago
Jul 28, 2016
Sell 184 K USD
Rush Gregory S
Executive VP and CFO
- 4066
45.226 USD
8 years ago
Jul 20, 2016
Sell 3.05 M USD
Macdonald D. Jamie
Chief Executive Officer
- 71007
43 USD
8 years ago
Jul 15, 2016
Sell 246 K USD
Rush Gregory S
Executive VP and CFO
- 5917
41.497 USD
8 years ago
Jul 11, 2016
Sell 715 K USD
Gaenzle Christopher L
CAO, GC & Sec
- 17795
40.1914 USD
8 years ago
Jul 11, 2016
Sell 117 K USD
Gaenzle Christopher L
CAO, GC & Sec
- 2906
40.253 USD
8 years ago
Jul 11, 2016
Sell 48.9 K USD
Gaenzle Christopher L
CAO, GC & Sec
- 1217
40.177 USD
8 years ago
Jul 01, 2016
Sell 16 K USD
Breckon Robert W
Director
- 421
37.97 USD
8 years ago
Jul 01, 2016
Sell 51.6 K USD
Rush Gregory S
Executive VP and CFO
- 1358
37.97 USD
8 years ago
Jun 14, 2016
Sell 44.1 K USD
Gaenzle Christopher L
CAO, GC & Sec
- 1100
40.052 USD
8 years ago
Jun 15, 2016
Sell 29.3 K USD
Gaenzle Christopher L
CAO, GC & Sec
- 728
40.215 USD
8 years ago
Jun 15, 2016
Sell 158 K USD
Gaenzle Christopher L
CAO, GC & Sec
- 3928
40.1598 USD
8 years ago
Jun 14, 2016
Sell 78.1 K USD
Gaenzle Christopher L
CAO, GC & Sec
- 1946
40.1123 USD
8 years ago
Jun 06, 2016
Sell 6.23 M USD
Gibertini Michael
President Clinical Development
- 144682
43.0528 USD
8 years ago
Jun 06, 2016
Sell 717 K USD
Gibertini Michael
President Clinical Development
- 16652
43.0494 USD
8 years ago
Jun 06, 2016
Sell 594 K USD
Gibertini Michael
President Clinical Development
- 13751
43.1851 USD
8 years ago
Jun 06, 2016
Sell 396 K USD
Gibertini Michael
President Clinical Development
- 9034
43.8318 USD
8 years ago
Jun 06, 2016
Sell 38.4 K USD
Gibertini Michael
President Clinical Development
- 877
43.816 USD
8 years ago
Jun 06, 2016
Sell 48.1 K USD
Gibertini Michael
President Clinical Development
- 1100
43.7566 USD
8 years ago
Jun 06, 2016
Sell 1.14 M USD
Gibertini Michael
President Clinical Development
- 26394
43.05 USD
8 years ago
Jun 06, 2016
Sell 64.7 K USD
Gibertini Michael
President Clinical Development
- 1476
43.843 USD
8 years ago
Jun 01, 2016
Sell 20.5 K USD
Breckon Robert W
Director
- 471
43.549 USD
8 years ago
Jun 02, 2016
Sell 94.4 K USD
Breckon Robert W
Director
- 2173
43.46 USD
8 years ago
May 06, 2016
Sell 177 M USD
ONTARIO TEACHERS PENSION PLAN BOARD
director, 10 percent owner:
- 3912946
45.12 USD
8 years ago
Apr 18, 2016
Sell 5.74 M USD
Ogle James T.
Director
- 114806
50 USD
8 years ago
Apr 12, 2016
Sell 1.7 M USD
Macdonald D. Jamie
Chief Executive Officer
- 35503
48 USD
8 years ago
Apr 01, 2016
Sell 367 K USD
Gibertini Michael
President Clinical Development
- 9000
40.782 USD
8 years ago
Mar 01, 2016
Sell 359 K USD
Gibertini Michael
President Clinical Development
- 9000
39.853 USD
8 years ago
Feb 04, 2016
Sell 96.3 K USD
Breckon Robert W
Director
- 2366
40.7 USD
8 years ago
Feb 04, 2016
Sell 16.8 K USD
Breckon Robert W
Director
- 421
40 USD
8 years ago
Feb 04, 2016
Sell 42.2 K USD
Breckon Robert W
Director
- 1095
38.58 USD
8 years ago
Feb 01, 2016
Sell 324 K USD
Gibertini Michael
President Clinical Development
- 8000
40.449 USD
8 years ago
Feb 01, 2016
Sell 41.6 K USD
Gibertini Michael
President Clinical Development
- 1000
41.56 USD
8 years ago
Feb 01, 2016
Sell 642 K USD
Rush Gregory S
Executive VP and CFO
- 16000
40.128 USD
8 years ago
Feb 01, 2016
Sell 72.8 K USD
Rush Gregory S
Executive VP and CFO
- 1752
41.56 USD
8 years ago
Jan 04, 2016
Sell 274 K USD
Gibertini Michael
President Clinical Development
- 5900
46.473 USD
8 years ago
Jan 04, 2016
Sell 147 K USD
Gibertini Michael
President Clinical Development
- 3100
47.517 USD
8 years ago
Dec 31, 2015
Sell 187 K USD
Rush Gregory S
Executive VP and CFO
- 4022
46.52 USD
8 years ago
Dec 31, 2015
Sell 216 K USD
Rush Gregory S
Executive VP and CFO
- 4533
47.56 USD
8 years ago
Dec 31, 2015
Sell 1.31 M USD
Rush Gregory S
Executive VP and CFO
- 26948
48.52 USD
8 years ago
Dec 31, 2015
Sell 32.7 K USD
Gaenzle Christopher L
CAO, GC & Sec
- 700
46.67 USD
8 years ago
Dec 31, 2015
Sell 37.5 K USD
Gaenzle Christopher L
CAO, GC & Sec
- 800
46.83 USD
8 years ago
Dec 31, 2015
Sell 33.5 K USD
Gaenzle Christopher L
CAO, GC & Sec
- 700
47.89 USD
8 years ago
Dec 31, 2015
Sell 57.8 K USD
Gaenzle Christopher L
CAO, GC & Sec
- 1200
48.15 USD
8 years ago
Dec 31, 2015
Sell 133 K USD
Gaenzle Christopher L
CAO, GC & Sec
- 2734
48.6 USD
8 years ago
Dec 31, 2015
Sell 162 K USD
Gaenzle Christopher L
CAO, GC & Sec
- 3334
48.56 USD
8 years ago
Dec 29, 2015
Sell 486 K USD
Ogle James T.
Director
- 9717
50.062 USD
8 years ago
Dec 07, 2015
Sell 254 K USD
Gaenzle Christopher L
CAO, GC & Sec
- 5676
44.695 USD
8 years ago
Dec 07, 2015
Sell 6.63 K USD
Gaenzle Christopher L
CAO, GC & Sec
- 147
45.103 USD
8 years ago
Dec 07, 2015
Sell 203 K USD
Gaenzle Christopher L
CAO, GC & Sec
- 4540
44.695 USD
8 years ago
Dec 07, 2015
Sell 5.37 K USD
Gaenzle Christopher L
CAO, GC & Sec
- 119
45.103 USD
8 years ago
Dec 08, 2015
Sell 289 K USD
Gaenzle Christopher L
CAO, GC & Sec
- 8169
35.357 USD
8 years ago
Dec 08, 2015
Sell 295 K USD
Gaenzle Christopher L
CAO, GC & Sec
- 6534
45.134 USD
8 years ago
Dec 07, 2015
Sell 1.47 M USD
Rush Gregory S
Executive VP and CFO
- 32871
44.695 USD
8 years ago
Dec 07, 2015
Sell 38.5 K USD
Rush Gregory S
Executive VP and CFO
- 854
45.103 USD
8 years ago
Dec 08, 2015
Sell 2.15 M USD
Rush Gregory S
Executive VP and CFO
- 47310
45.43 USD
8 years ago
Dec 07, 2015
Sell 132 M USD
ONTARIO TEACHERS PENSION PLAN BOARD
director, 10 percent owner:
- 2934709
45 USD
8 years ago
Dec 07, 2015
Sell 66 M USD
ONTARIO TEACHERS PENSION PLAN BOARD
director, 10 percent owner:
- 1467354
45 USD
8 years ago
Dec 01, 2015
Sell 110 K USD
Gibertini Michael
President Clinical Development
- 2415
45.707 USD
8 years ago
Dec 01, 2015
Sell 243 K USD
Gibertini Michael
President Clinical Development
- 5200
46.652 USD
8 years ago
Dec 01, 2015
Sell 65.7 K USD
Gibertini Michael
President Clinical Development
- 1385
47.429 USD
9 years ago
Nov 02, 2015
Sell 375 K USD
Gibertini Michael
President Clinical Development
- 9000
41.7 USD
9 years ago
Sep 14, 2015
Sell 1.05 M USD
Rush Gregory S
Executive VP and CFO
- 23426
44.74 USD
9 years ago
Sep 14, 2015
Sell 413 K USD
Rush Gregory S
Executive VP and CFO
- 9000
45.88 USD
9 years ago
Aug 31, 2015
Sell 2.26 M USD
Ogle James T.
Director
- 55000
41.12 USD
9 years ago
Aug 31, 2015
Sell 318 K USD
Gaenzle Christopher L
CAO, GC & Sec
- 7743
41.13 USD
9 years ago
Aug 31, 2015
Sell 399 K USD
Gaenzle Christopher L
CAO, GC & Sec
- 9678
41.19 USD
9 years ago
Aug 17, 2015
Sell 170 M USD
ONTARIO TEACHERS PENSION PLAN BOARD
director, 10 percent owner:
- 3857525
44 USD
9 years ago
Aug 12, 2015
Sell 130 K USD
Breckon Robert W
Director
- 2964
44 USD
9 years ago
Aug 12, 2015
Sell 238 K USD
Breckon Robert W
Director
- 5417
44 USD
9 years ago
Aug 12, 2015
Sell 2.08 M USD
Macdonald D. Jamie
Chief Executive Officer
- 47341
44 USD
9 years ago
Aug 12, 2015
Sell 426 K USD
Macdonald D. Jamie
Chief Executive Officer
- 9680
44 USD
9 years ago
May 14, 2015
Sell 114 M USD
ONTARIO TEACHERS PENSION PLAN BOARD
director, 10 percent owner:
- 3846857
29.68 USD
9 years ago
May 14, 2015
Sell 73.4 M USD
ONTARIO TEACHERS PENSION PLAN BOARD
director, 10 percent owner:
- 2471750
29.68 USD
9 years ago
May 11, 2015
Sell 32.3 K USD
Rush Gregory S
Executive VP and CFO
- 1088
29.68 USD
9 years ago
May 11, 2015
Sell 15.5 K USD
Ogle James T.
Director
- 521
29.68 USD
9 years ago
May 11, 2015
Sell 10.6 K USD
Breckon Robert W
Director
- 358
29.68 USD
9 years ago
May 07, 2015
Sell 370 K USD
Rush Gregory S
Executive VP and CFO
- 12455
29.68 USD
9 years ago
May 07, 2015
Sell 1.48 M USD
Gibertini Michael
President Clinical Development
- 50000
29.68 USD
9 years ago
May 07, 2015
Sell 121 K USD
Breckon Robert W
Director
- 4081
29.68 USD
9 years ago
May 07, 2015
Sell 177 K USD
Ogle James T.
Director
- 5951
29.68 USD
20 years ago
Dec 08, 2003
Sell 6 K USD
GAMMANS RICHARD E SR
Executive VP, R&D
- 20000
0.3 USD
7. News
Are Investors Missing The Forest? 35% Stock Drop Masks The International Potential Of This Weed Company InterCure Ltd. INCR has shown resilience in its H1 2024 performance despite facing significant challenges, according to equity research by Pablo Zuanic of Zuanic & Associates. benzinga.com - 2 months ago
InterCure Announces First Half of 2024 Results: Revenue of NIS 126 million and Adjusted EBITDA of NIS 21 million NEW YORK and HERZLIYA, Israel, Aug. 29, 2024 (GLOBE NEWSWIRE) -- InterCure  Ltd . (NASDAQ: INCR) (TASE: INCR) ("InterCure" or the "Company") is pleased to announce its financial and operating results for the six months ended June 30, 2024. All amounts are expressed in New Israeli Shekels (NIS), unless otherwise noted. globenewswire.com - 2 months ago
InterCure Announces Expansion of its Strategic partnership with Cookies to Germany NEW YORK & HERZLIYA, Israel--(BUSINESS WIRE)--InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), the leading vertically integrated medical cannabis company outside of North America, is announcing a new strategic agreement with Cookies, the globally recognized cannabis brand, to cultivate, manufacture, import and distribute Cookies' branded products, produced from its cultivation and manufacturing facilities, initially in 8 licensed branded pharmacies across. businesswire.com - 2 months ago
InterCure: A Cannabis Industry Leader Still Flying Under The Radar InterCure is a leading pharmaceutical/medical cannabis company based in Israel and a global leader outside North America. Despite the damage the Hamas attack and the state of war in Israel caused, the company managed to sustain operations and present a positive 2023 ER. The company is entitled to full compensation from the Israeli government for the damage taken. seekingalpha.com - 4 months ago
InterCure to Participate in Canaccord Genuity's 8th Annual Global Cannabis Conference NEW YORK & HERZLIYA, Israel--(BUSINESS WIRE)--InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc), the leading medical cannabis company outside of North America, today announced that it will participate in the Canaccord Genuity 8th Annual Global Cannabis Conference. The conference is scheduled for tomorrow, May 23, 2024, at the Westin NY Grand Central Hotel in New York City. This prestigious event will bring together senior management teams from leading cannabis companies including InterCu. businesswire.com - 5 months ago
InterCure Announces FY2023 Results: Revenue of NIS 356 million and Adjusted EBITDA of NIS 61 million NEW YORK & HERZLIYA, Israel--(BUSINESS WIRE)--InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) ("InterCure" or the "Company") today announced results for the full year ending December 31, 2023. All amounts are expressed in New Israeli Shekels (NIS), unless otherwise noted. FY2023 Financial Highlights and Milestones Annual revenue for the year ending December 31, 2023 was NIS 356 million, and the adjusted EBITDA for the year ending December 31, 2023 was NIS 61 million, approximately 17% of revenues, a. businesswire.com - 6 months ago
InterCure: Bargain Israel Cannabis Play InterCure Ltd. has faced challenges due to the conflict with Hamas, including not having access to a prime facility in Israel, but is expected to recover. The cannabis market in Israel is still limited to medical use, with expansion to medical cannabis patient access to grow the market in 2024. InterCure stock is cheap at only about 1x sales, with catalysts for growth in 2024 and beyond. seekingalpha.com - 6 months ago
InterCure Congratulates Germany on Cannabis Reform, Expanding its Global Footprint NEW YORK & HERZLIYA, Israel--(BUSINESS WIRE)---- $INCR #CANNABIS--InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), the leading medical cannabis company outside of North America, is thrilled to congratulate The Federal Republic of Germany for the passing of the “CannG” Cannabis Act, which is expected to take effect on April 1, 2024. On the backdrop of this monumental development, InterCure expects to launch a series of products in Germany in the coming months. While the Canna. businesswire.com - 7 months ago
PESG Industry Updates: Germany's Cannabis Act and Its Impact on the Medical Cannabis Landscape LONDON--(BUSINESS WIRE)---- $INCR #CannG--The PESG Research has released an industry update following the regulatory shifts in Germany. Germany is expected to pass the Cannabis Act today (Friday), heralding a transformative era for the medical cannabis industry. This legislative milestone, by removing cannabis from the 'narcotics act', is set to significantly ease the prescription process for medical cannabis, heralding profound implications for medical professionals, patients, and companies operating within th. businesswire.com - 8 months ago
InterCure Provides an Update Regarding Nir Oz Facility NEW YORK, and HERZLIYA, Israel, Feb. 13, 2024 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Compan y"), the leading medical cannabis company in Israel and outside of North America, reports today that, further to the Company's press release issued on October 17, 2023, in which the Company provided an update regarding the status of the security situation in Israel, and its impact on the Company and its employees, the Company is providing an additional update regarding the status of its facility in Kibbutz Nir Oz (the “Southern Israel Site”). globenewswire.com - 9 months ago
InterCure Signs Definitive Agreement to Acquire Leon Cannabis Pharmacy Chain NEW YORK, and HERZLIYA, Israel, Jan. 31, 2024 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Compan y"), the leading medical cannabis company in Israel and outside of North America, announced today that it has entered into a share purchase agreement (the “Agreement”) with the shareholders of Leon Pharm Ltd. (the “Sellers”, and “Leon Pharm ”, respectively) to purchase Leon Pharm, a leading, Israel-based pharmacy chain specializing in dispensing medical cannabis in Israel, by way of a share purchase of all of the issued and outstanding share capital of Leon Pharm (the “Transaction”). globenewswire.com - 9 months ago
InterCure Wins Cannolam Arbitration Proceeding NEW YORK and HERZLIYA, Israel , Oct. 31, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Compan y"), the leading medical cannabis company in Israel and outside of North America, reports today that, further to the Company's press release issued on August 31, 2023, in which the Company reported that the Tel Aviv-Jaffa District Court dismissed the lawsuit that filed against the Company by minority shareholders of its subsidiary, Cannolam Ltd. (“Cannolam”), and the parties agreed on a binding arbitration process (the “Arbitration”), in which the amount owed to the Company and the parties will be determined and paid as part of a full separation process, the Company hereby reports that the Arbitration has been concluded, and the arbitrator has decided in favor of the Company on most of the claims presented to him by the Company, while rejecting almost all of the claims presented by the minority shareholders. globenewswire.com - 1 year ago
8. Profile Summary

InterCure Ltd. INCR

image
COUNTRY IL
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 53.5 M
Dividend Yield 0.00%
Description InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Israel and internationally. It offers dried cannabis inflorescences and cannabis extract mixed with oil. The company also invests in biomed sector. InterCure Ltd. was incorporated in 1994 and is headquartered in Herzliya, Israel.
Contact 85 Medinat ha-Yehudim Street, Herzliya, 4676670 https://www.intercure.co
IPO Date Jan. 28, 2019
Employees 270
Officers Mr. Alexander Rabinovich Chief Executive Officer & Director Mr. Amos Cohen Chief Financial Officer Einat Zehavi Vice President of Sales